Facebook
Twitter
Telegram
Report an ErrorEnveric Biosciences Balance Sheet 2011-2024 | ENVB
Annual Balance Sheet Enveric Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-17.2 M | -1.58 M | 4.45 M | 3.84 M | 2.3 M | 3.65 M | 4.36 M | -5.08 K | 1.75 K | 6.62 K | -18.2 K | |
Long Term Debt |
- | 68.9 K | - | - | - | 2.38 M | 1.54 M | 5 M | - | - | - | - |
Long Term Debt Current |
63.8 K | 107 K | - | 120 K | - | 750 K | 1.54 M | - | - | - | - | - |
Total Non Current Liabilities |
- | 1.68 M | - | - | 4.19 M | 2.38 M | 15.1 M | 5 M | - | - | - | - |
Total Current Liabilities |
4 M | 2.74 M | - | 14.5 M | 14.7 M | 30.4 M | 12.7 M | 8.58 M | 8.96 K | 24.7 K | 25.7 K | 17.9 K |
Total Liabilities |
4 M | 4.41 M | 681 K | 14.4 M | 18.9 M | 32.7 M | 27.8 M | 13.6 M | 8.96 K | 24.7 K | 25.7 K | 17.9 K |
Deferred Revenue |
- | - | - | - | - | - | - | 44.8 K | - | - | - | - |
Retained Earnings |
-79.2 M | -60.7 M | -11.8 M | -40.5 M | -34.5 M | -15 M | -3.83 M | -1.05 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M |
Total Assets |
19.6 M | 26.7 M | 4.1 M | 25 M | 29.6 M | 52.2 M | 39.5 M | 13.8 M | 5.08 K | 4.47 K | 5.6 K | 22.4 K |
Cash and Cash Equivalents |
17.7 M | 17.4 M | 1.58 M | 431 K | 1.37 M | 4.88 M | 1.38 M | 1.88 M | 5.08 K | 249 | 1.38 K | 18.2 K |
Book Value |
15.6 M | 22.3 M | 3.42 M | 10.6 M | 10.8 M | 19.4 M | 11.7 M | 259 K | -3.87 K | -20.2 K | -20.1 K | 4.56 K |
Total Shareholders Equity |
14.7 M | 22.3 M | 3.42 M | -1.81 M | 10.8 M | 19.4 M | 11.7 M | 259 K | -3.87 K | -20.2 K | -20.1 K | 4.56 K |
All numbers in USD currency
Quarterly Balance Sheet Enveric Biosciences
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | 9.87 K | 40.1 K | 68.9 K | - | - | - | - | 678 K | 708 K | - | 740 K | 199 K | 170 K | - | - | 1.7 K | 927 K | 1.03 M | 1.13 M | 1.13 M | 1.13 M | 1.13 M | 1.54 M | 1.54 M | 1.54 M | 1.54 M | 5 M | - | - | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 4.66 M | 3.64 M | 5.64 M | 2.33 M | - | - | - | - | 825 K | 1.86 M | - | 1.17 M | 4.45 M | 1.17 M | 4.64 M | 4.19 M | 4.19 M | 4.19 M | 4.19 M | 2.38 M | 2.38 M | 2.38 M | 2.38 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 7.25 M | 5.97 M | 7.74 M | 4.41 M | 14.4 M | 4.88 M | 6.79 M | 681 K | 681 K | 681 K | 681 K | 1.92 M | 14.7 M | 14.7 M | 14.4 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 27.8 M | 27.8 M | 27.8 M | 27.8 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-93.1 M | -90.2 M | -83.9 M | -79.2 M | -70.5 M | -68.1 M | -65.3 M | -60.7 M | -18.6 M | -15.9 M | -15 M | -11.8 M | -11.8 M | -11.8 M | -11.8 M | -4.89 M | -40.5 M | -40.5 M | -40.5 M | -34.5 M | -34.5 M | -34.5 M | -34.5 M | -15 M | -15 M | -15 M | -15 M | -3.83 M | -3.83 M | -3.83 M | -3.83 M | -1.05 M | -1.05 M | -1.05 M | -1.05 M | -47.4 M | -47.4 M | -47.4 M | 415 K | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M | -47.4 M |
Total Assets |
6.62 M | 9.8 M | 15.9 M | 19.6 M | 30.9 M | 28.6 M | 32.2 M | 26.7 M | 69.8 M | 23.7 M | 25.8 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 109 K | 25.3 M | 25.3 M | 25 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 5.08 K | 9.13 K | 12 K | 3.44 M | 4.47 K | 4.47 K | 4.47 K | 4.47 K | 5.6 K | 5.6 K | 5.6 K | 5.6 K | 22.4 K | 22.4 K | 22.4 K | 22.4 K |
Cash and Cash Equivalents |
4.27 M | 7.08 M | 12.6 M | 17.7 M | 21.2 M | 18 M | 21.7 M | 17.4 M | 21.4 M | 20.6 M | 22.7 M | 1.58 M | 2.84 M | 2.09 M | 1.27 M | 431 K | 500 K | 431 K | 431 K | 1.37 M | 1.37 M | 1.37 M | 1.37 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 1.38 M | 1.38 M | 1.38 M | 1.38 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 5.08 K | 9.13 K | 7.79 K | 22.5 K | 249 | 249 | 249 | 249 | 1.38 K | 1.38 K | 1.38 K | 1.38 K | 18.2 K | 18.2 K | 18.2 K | 18.2 K |
Book Value |
- | - | - | 19.6 M | 23.6 M | 22.6 M | 24.4 M | 22.3 M | 55.4 M | 18.8 M | 19 M | 3.42 M | 3.42 M | 3.42 M | 3.42 M | -1.81 M | 10.6 M | 10.6 M | 10.6 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 259 K | 259 K | 259 K | 259 K | 5.08 K | 9.13 K | 12 K | 3.44 M | 4.47 K | 4.47 K | 4.47 K | 4.47 K | 5.6 K | 5.6 K | 5.6 K | 5.6 K | 22.4 K | 22.4 K | 22.4 K | 22.4 K |
Total Shareholders Equity |
2.44 M | 4.87 M | 10.4 M | 14.7 M | 22.8 M | 22 M | 24.4 M | 22.3 M | 55.4 M | 18.8 M | 19 M | 3.42 M | 3.42 M | 3.42 M | 3.42 M | -1.81 M | 10.6 M | 10.6 M | 10.6 M | -65.5 K | 10.8 M | 10.8 M | 10.8 M | 19.4 M | 12.2 M | 13.6 M | 14.8 M | 11.7 M | 4.75 M | 11.7 M | 11.7 M | 259 K | 259 K | 259 K | 259 K | -3.87 K | 6.83 K | 10 K | 425 K | -20.2 K | -20.2 K | -20.2 K | -20.2 K | -20.1 K | -20.1 K | -20.1 K | -20.1 K | 4.56 K | 4.56 K | 4.56 K | 4.56 K |
All numbers in USD currency